Choline
|
Basic information |
| Metabolite name | Choline |
 | HMDB0000097 |
 |
C00114 |
 |
305 |
| Synonyms | NA |
| No. of studies | 47 |
|
Basic information |
| Metabolite name | Choline |
| HMDB0000097 |
|
C00114 |
|
305 |
| Synonyms | NA |
| No. of studies | 47 |
|
Relationship between Choline and depression (count: 47) |
| Study | Study Type  |
Comparison groups | Tissue | Organism | Up/Down regulated |
| Study M006 | Type1 | depressed group vs. control group | Plasma | Human | Up |
| Study M015 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M015 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + Xiaoyaosan Nan group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M015 | Type2 | CUMS + Xiaoyaosan Bei group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M017 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M036 | Type1 | MDD group vs. control group | Urine | Human | Down |
| Study M043 | Type1 | chronic hepatitis B patients with MDD group vs. without MDD group | Urine | Human | Up |
| Study M044 | Type2 | CUMS + rTMS group vs. CUMS + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M044 | Type2 | CUMS + rTMS group vs. CUMS + sham rTMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M044 | Type3 | control + rTMS group vs. control + sham rTMS group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M044 | Type3 | control + rTMS group vs. control + sham rTMS group | Hippocampus | Sprague-Dawley rat | Up |
| Study M050 | Type3 | 2h Ketamine group vs. control group | Hippocampus | C57BL/6 mouse | Up |
| Study M055 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Down |
| Study M056 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M056 | Type2 | CUMS + high dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M056 | Type2 | CUMS + middle dose of FFCGF group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M059 | Type1 | depressed group vs. control group | Plasma | Human | Down |
| Study M059 | Type2 | Xiaoyaosan-treated depressed group 9-week vs. baseline | Plasma | Human | Up |
| Study M102 | Type1 | moderate MDD group vs. control group | Urine | Human | Down |
| Study M102 | Type1 | severe MDD group vs. control group | Urine | Human | Up |
| Study M1023 | Type1 | CRS group vs. control group | Faece | C57BL/6 J mouse | Up |
| Study M107 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M107 | Type1 | Glu group vs. control group | PC12 cell | Rat | Up |
| Study M108 | Type1 | CUMS group vs. control group | Liver | Sprague-Dawley rat | Up |
| Study M108 | Type2 | CUMS + VBBR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M108 | Type2 | CUMS + BR group vs. CUMS group | Liver | Sprague-Dawley rat | Down |
| Study M1090 | Type1 | CUMS group vs. control group | Plasma | BALb/c mouse | Down |
| Study M1090 | Type2 | CUMS + hyperbaric oxygen treatment group vs. CUMS group | Plasma | BALb/c mouse | Up |
| Study M1090 | Type3 | hyperbaric oxygen treatment group vs. control group | Plasma | BALb/c mouse | Up |
| Study M1093 | Type1 | CSDS group vs. control group | Serum | C57BL/6N mouse | Down |
| Study M116 | Type3 | ketamine group vs. control group | Cerebrospinal fluid | Sprague-Dawley rat | Up |
| Study M120 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M133 | Type1 | CUMS group vs. control group | Plasma | Sprague-Dawley rat | Up |
| Study M133 | Type2 | CUMS + XY-A group vs. CUMS group | Plasma | Sprague-Dawley rat | Down |
| Study M134 | Type1 | CRS group vs. control group | Urine | Sprague-Dawley rat | Down |
| Study M134 | Type2 | CRS + BH group vs. CRS group | Urine | Sprague-Dawley rat | Up |
| Study M140 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M140 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + paroxetine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M140 | Type2 | CUMS + SJ group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M473 | Type1 | high-fat diet group vs. control group | Prefrontal cortex | C57BL/6J mouse | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hypothalamus | Wistar rat | Down |
| Study M479 | Type1 | diabetic depression group vs. control group | Hippocampus | Wistar rat | Down |
| Study M486 | Type1 | CORT group vs. control group | PC12 cell | Rat | Up |
| Study M519 | Type1 | susceptible group vs. control group | Prefrontal cortex | C57BL/6N mouse | Down |
| Study M532 | Type1 | MDD group vs. control group | Plasma | Human | Down |
| Study M541 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M541 | Type2 | CUMS + low dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M541 | Type2 | CUMS + high dose of AS group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M552 | Type2 | CUMS + high dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + median dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + augmentation treatment group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M552 | Type2 | CUMS + low dose of Chaigui group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M578 | Type1 | restraint stress offspring group vs. control offspring group | Hippocampus | Sprague-Dawley rat | Up |
| Study M584 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M584 | Type2 | CUMS + high dose of Xiaoyaosan group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M584 | Type2 | CUMS + venlafaxine group vs. CUMS group | Serum | Sprague-Dawley rat | Down |
| Study M629 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Down |
| Study M629 | Type2 | CUMS + middle dose of coumaroylspermidine extract group vs. CUMS group | Serum | Sprague-Dawley rat | Up |
| Study M631 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Down |
| Study M631 | Type2 | CUMS + high dose of iridoid-rich fraction of V. jatamansi group vs. CUMS group | Serum | Kunming mouse | Up |
| Study M680 | Type1 | 5-fluorouracil group vs. control group | Prefrontal cortex | Sprague-Dawley rat | Up |
| Study M740 | Type1 | CUMS group vs. control group | Soleus muscle | Sprague-Dawley rat | Down |
| Study M740 | Type2 | CUMS + endurance exercise group vs. CUMS group | Soleus muscle | Sprague-Dawley rat | Up |
| Study M769 | Type1 | CSDS group vs. control group | Amygdala | Sprague-Dawley rat | Up |
| Study M772 | Type1 | CUMS group vs. control group | Amygdala | Sprague-Dawley rat | Down |
| Study M773 | Type1 | antenatal depression group vs. non-antenatal depression group | Serum | Human | Down |
| Study M791 | Type1 | CUMS group vs. control group | Cecum | Sprague-Dawley rat | Down |
| Study M809 | Type1 | CUMS group vs. control group | Serum | Kunming mouse | Up |
| Study M809 | Type2 | CUMS + Milletia speciosa Champ group vs. CUMS group | Serum | Kunming mouse | Down |
| Study M820 | Type3 | single-dose nefazodone group vs. single-dose control group | Brain | ICR mouse | Down |
| Study M820 | Type3 | multiple-dose nefazodone group vs. multiple-dose control group | Brain | ICR mouse | Down |
| Study M821 | Type1 | CUMS group vs. control group | Faece | Sprague-Dawley rat | Up |
| Study M840 | Type1 | A1/A2 beta-casein group vs. control group | Frontal cortex | Wistar rat | Down |
| Study M913 | Type2 | responder group, post-escitalopram treatment vs. baseline | Plasma | Human | Up |
| Study M924 | Type1 | CUMS group vs. control group | Serum | Sprague-Dawley rat | Up |
| Study M928 | Type1 | CUMS group vs. control group | Faece | C57BL/6 mouse | Up |
| Study M940 | Type1 | CUMS group vs. control group | Cerebral cortex | Sprague-Dawley rat | Up |
| Study M965 | Type1 | CUMS depression group vs. control group | Faece | Sprague-Dawley rat | Up |